- Report
- March 2024
- 188 Pages
Global
From €3219EUR$3,374USD£2,739GBP
€3577EUR$3,749USD£3,043GBP
- Report
- May 2024
- 372 Pages
Global
From €5200EUR$5,450USD£4,424GBP
- Report
- November 2023
- 146 Pages
Global
From €2384EUR$2,499USD£2,028GBP
- Report
- October 2023
- 150 Pages
Global
From €4628EUR$4,850USD£3,937GBP
- Report
- May 2024
- 100 Pages
Africa
From €3621EUR$3,795USD£3,080GBP
- Report
- April 2024
- 80 Pages
United States
From €2476EUR$2,595USD£2,106GBP
- Report
- May 2024
- 546 Pages
Global
From €6674EUR$6,995USD£5,678GBP
- Report
- May 2024
- 541 Pages
Global
From €6674EUR$6,995USD£5,678GBP
- Report
- August 2023
- 1500 Pages
Global
From €8349EUR$8,750USD£7,102GBP
- Report
- October 2023
- 253 Pages
Global
From €4723EUR$4,950USD£4,018GBP
- Report
- May 2024
- 199 Pages
Global
From €3219EUR$3,374USD£2,739GBP
€3577EUR$3,749USD£3,043GBP
- Report
- May 2024
- 158 Pages
Global
From €5200EUR$5,450USD£4,424GBP
- Report
- January 2024
- 200 Pages
Global
From €4771EUR$5,000USD£4,059GBP
- Report
- December 2023
- 200 Pages
Global
From €3817EUR$4,000USD£3,247GBP
- Report
- January 2024
- 182 Pages
Global
From €4675EUR$4,900USD£3,977GBP
- Report
- June 2023
- 115 Pages
Global
From €4294EUR$4,500USD£3,653GBP
- Report
- January 2024
- 200 Pages
Global
From €3960EUR$4,150USD£3,369GBP
- Report
- February 2024
- 72 Pages
South Korea
From €4771EUR$5,000USD£4,059GBP
- Report
- January 2023
- 195 Pages
Latin America
From €4771EUR$5,000USD£4,059GBP
- Report
- June 2022
- 55 Pages
India
From €4771EUR$5,000USD£4,059GBP
The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more